Skip to content

US · MESO · BIOTECHNOLOGY

Mesoblast Limited (MESO) intrinsic value and stock valuation

$10.89as of 2026-11-21 · Mkt cap 1.94B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Mesoblast Limited DCF and intrinsic value

InvestorsCraft values MESO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MESO’s statements →

Mesoblast Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Melbourne, VIC 3000 mesoblast.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$17.2M-11.8% 5y CAGRd
20112025
Net income
-$-102.14M
20112025
Free cash flow
-$-50.68M
20112025
Total equity
$597.4M+1.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$17.2M$5.9M$7.5M$10.2M$7.46M
Operating income-$-62.44M-$-84.15M-$-69.29M-$-80.57M-$-109.1M
Net income-$-102.14M-$-87.96M-$-81.89M-$-91.35M-$-98.81M
EPSd-$-845.67K-$-891.46K-$-975.69K-$-1.34M-$-1.63M
Operating cash flow-$-49.95M-$-48.46M-$-63.27M-$-65.78M-$-106.68M
Capital expenditure-$-730K-$-330K-$-310K-$-230K-$-1.65M
Free cash flow-$-50.68M-$-48.79M-$-63.58M-$-66.01M-$-108.33M
Total assets$784.7M$669.2M$669.4M$662.1M$744.7M
Total debt$128.2M$118.9M$116.5M$106.9M$105.5M
Net debt-$-33M$56.4M$45.6M$46.9M-$-31.39M
Total equity$597.4M$480.4M$501.8M$497M$581.4M
Cash and short-term investments$161.2M$62.6M$70.9M$60M$136.9M
Income statement
20252024202320222021
Revenue$17.2M$5.9M$7.5M$10.2M$7.46M
Cost of revenue$5.13M$41.1M$54.9M$63.6M$85.7M
Gross profit$12.1M-$-35.17M-$-47.42M-$-53.36M-$-78.28M
Research and development expenses$34.8M$25.4M$27.2M$32.8M$53M
Selling, general and administrative expenses$39.3M$23.6M$53.1M$58M$63.6M
Other expenses$400K$0.00$0.00$30.8M$32.7M
Operating expenses$74.5M$49M$76.8M$90.8M$115.1M
Cost and expenses$79.6M$90.1M$76.8M$90.8M$115.1M
Interest income$3.55M$1.82M$830K$0.00$0.00
Interest expense$22.9M$20.7M$19.4M$17.3M$10.7M
Depreciation and amortization$6.4M$1.9M$4.11M$4.38M$4.26M
Ebitda-$-73.66M-$-56.08M-$-58.55M-$-76.57M-$-84.65M
Operating income-$-62.44M-$-84.15M-$-69.29M-$-80.57M-$-109.1M
Total other income/expenses, net-$-39.37M-$-4M-$-12.81M-$-10.48M$9.47M
Income before tax-$-101.81M-$-88.15M-$-82.1M-$-91.59M-$-99.63M
Income tax expense$330K-$-190K-$-210K-$-240K-$-820K
Net income-$-102.14M-$-87.96M-$-81.89M-$-91.35M-$-98.81M
Weighted average shares outstanding$120.8M$98.7M$83.8M$68.3M$60.5M
Weighted average diluted shares outstanding$120.8M$98.7M$83.9M$68.3M$60.5M
Balance sheet
20252024202320222021
Cash and short-term investments$161.2M$62.6M$70.9M$60M$136.9M
Net receivables$14.9M$21M$7M$4.4M$4.59M
Inventory$22.3M$0.00$0.00$0.00-$-250K
Total current assets$204.4M$86.5M$81.7M$69.8M$148.2M
Property, plant and equipment, net$5.82M$3.84M$6.49M$9.96M$12.1M
Goodwill and intangible assets$571.8M$575.7M$577.2M$578.7M$580.6M
Long-term investments$1.39M$1.01M$1.76M$1.76M$2.08M
Total non-current assets$580.3M$582.7M$587.8M$592.3M$596.5M
Total assets$784.7M$669.2M$669.4M$662.1M$744.7M
Accounts payable$19.1M$7.07M$20.1M$23.1M$19.6M
Short-term debt$56.8M$16.5M$10M$8.2M$56M
Deferred revenue$0.00$0.00$6.4M$17.9M-$-55.97M
Total current liabilities$102.6M$73.2M$42M$51.4M$94.3M
Long-term debt$71.3M$102.4M$106.5M$98.7M$49.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$84.6M$115.6M$125.6M$113.7M$69.1M
Capital lease obligations$6.26M$4.58M$7.73M$10.3M$11.3M
Total liabilities$187.2M$188.8M$167.6M$165.1M$163.3M
Common stock$1.51B$1.31B$1.25B$1.17B$1.16B
Retained earnings-$-1.01B-$-908.76M-$-820.8M-$-738.92M-$-647.57M
Accumulated other comprehensive income (loss)$99.5M$78.3M$73.5M$70.7M$65.8M
Total equity$597.4M$480.4M$501.8M$497M$581.4M
Total investments$1.39M$1.01M$1.76M$1.76M$2.08M
Total debt$128.2M$118.9M$116.5M$106.9M$105.5M
Net debt-$-33M$56.4M$45.6M$46.9M-$-31.39M
Cash flow statement
20252024202320222021
Net income-$-102.14M-$-87.96M-$-81.89M-$-91.35M-$-98.81M
Depreciation and amortization$6.4M$4.67M$4.11M$4.38M$4.26M
Stock-based compensation$22.1M$5.87M$3.65M$5.54M$12.5M
Change in working capital-$-3.04M-$-2.63M-$-2.47M$4.87M-$-8.42M
Accounts receivable$6.29M-$-15.47M-$-120K$140K-$-1.74M
Inventory$830K$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-49.95M-$-48.46M-$-63.27M-$-65.78M-$-106.68M
Investments in property, plant and equipment-$-680K-$-270K-$-310K-$-230K-$-1.65M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$120K-$-100K-$-190K-$-230K-$-1.65M
Common stock issued$161.2M$65.4M$88.6M$210K$106.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$147.3M$40.3M$74.5M-$-9.87M$114.5M
Net change in cash$98.6M-$-8.36M$10.9M-$-76.43M$7.55M
Cash at end of period$161.6M$63M$71.3M$60.5M$136.9M
Operating cash flow-$-49.95M-$-48.46M-$-63.27M-$-65.78M-$-106.68M
Capital expenditure-$-730K-$-330K-$-310K-$-230K-$-1.65M
Free cash flow-$-50.68M-$-48.79M-$-63.58M-$-66.01M-$-108.33M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Mesoblast Limited

        Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.

        CEO
        Silviu Itescu
        Employees
        81
        Beta
        0.81

        Explore

        Frequently asked questions

        What is the intrinsic value of Mesoblast Limited (MESO)?

        Mesoblast Limited (MESO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MESO undervalued?

        MESO trades at a price of $10.89 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.